pharmaceuticals march 24 2005 solvay sa nv acquisition of fournier pharma immediate boost to sales and profits with strong pipeline fit 2 table contents executive summary adding a franchise in dyslipidemia cardiovascular business r&d fenofibrate market strategic financial impact on the group conclusion background information 4 announcement signature memorandum understanding for 100 capital subject final satisfactory due diligences be conducted after next four weeks approval relevant regulatory authorities consultation procedure workers representatives progress proposed price eur 1300 m debt free paid cash conditional payments based future performances completion expected during summer 5 strategy s focuses sustainable profitable growth selected areas chemicals plastics intention acquire is aimed at accelerating
